Mario Taffurelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mario Taffurelli has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Donatella Santini
Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
4 shared publications - Margherita Serra
Breast Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
2 shared publications A. Musto
Osp. S.Orsola-Malpighi, Bologna, Italy; Servizio Medicina Nucleare, Osp. S. Orsola-Malpighi Bologna, Italy; Servizio di Anatomia Patologica, Ospedale S.Orsola-Malpighi Bologna, Italy; U.O. Chirurgia d’Urgenza, Bologna, Italy
1 shared publicationA. Quattrini Li
Centro Senologico Azienda Ospedaliera Universitaria Pisana Ospedale Santa Chiara, Pisa, Italy
1 shared publication- Alessandra Bernardi
University of Trento
1 shared publication - Alessandra Surace
Division of Gynecologic Oncology, Michele e Pietro Ferrero Hospital, 12060 Verduno, Italy
1 shared publication
Latest Publications
- 1 October 2020
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 46 (10) , 1861-1866
Aesthetic results following breast cancer surgery: A prospective study on 6515 cases from ten Italian Senonetwork breast centers
- 1 October 2020
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 46 (10) , 1861-1866
Aesthetic results following breast cancer surgery: A prospective study on 6515 cases from ten Italian Senonetwork breast centers
- Open Access
- 26 December 2018
- Published by Gavin Publishers in Journal of Surgery
- Vol. 9 (12)
Locoregional Control After Breast Conserving Treatment in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer
1. Abstract In the last decade Neoadjuvant Chemotherapy (NAC) has become more common for patients with operable breast cancer. Greatest advantage of this approach is that it can increase the proportion of patients who can be treated with Breast Conserving Therapy (BCT). This is a retrospective study of a prospective database regarding 573 patients, consecutively treated with BCT and ALND, among these 84 were treated with NAC. Primary end-point of this study was to evaluate long-term outcomes of patients treated with BCT after NAC. Secondarily we evaluated same outcomes in populations with comparable initial clinical stage; more over factors affecting the risk of developing a Locoregional Recurernce (LRR) were investigated. Incidence rate registered for LRR was 1/100 person per year for patients treated with adjuvant chemotherapy, while it is doubled in the NAC-group with 2/100 person per year. Ipsilateral breast tumour recurrences’ incidence rate was 1 IBTR per 100 persons per year in the first group and twice as much in the NAC-group. When considering only patients initially staged cT2, there is no significant difference in terms of outcome at 5 and 10 years. NAC shows equivalent outcomes compared to BCT and adjuvant chemotherapy especially when our case-series is analyzed by presenting clinical tumor stage, leading to satisfactory locoregional outcomes without affecting overall survival of patients, thus increasing considerably the rates of patients eligible for conservative treatment. 2. Keywords: Breast Cancer; Conservative Treatment; Locoregional Recurrences; Neoadjuvant Chemotherapy
- 26 December 2018
- Published by Gavin Publishers in Journal of Surgery
- Vol. 9 (12)
Open AccessLocoregional Control After Breast Conserving Treatment in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer
1. Abstract In the last decade Neoadjuvant Chemotherapy (NAC) has become more common for patients with operable breast cancer. Greatest advantage of this approach is that it can increase the proportion of patients who can be treated with Breast Conserving Therapy (BCT). This is a retrospective study of a prospective database regarding 573 patients, consecutively treated with BCT and ALND, among these 84 were treated with NAC. Primary end-point of this study was to evaluate long-term outcomes of patients treated with BCT after NAC. Secondarily we evaluated same outcomes in populations with comparable initial clinical stage; more over factors affecting the risk of developing a Locoregional Recurernce (LRR) were investigated. Incidence rate registered for LRR was 1/100 person per year for patients treated with adjuvant chemotherapy, while it is doubled in the NAC-group with 2/100 person per year. Ipsilateral breast tumour recurrences’ incidence rate was 1 IBTR per 100 persons per year in the first group and twice as much in the NAC-group. When considering only patients initially staged cT2, there is no significant difference in terms of outcome at 5 and 10 years. NAC shows equivalent outcomes compared to BCT and adjuvant chemotherapy especially when our case-series is analyzed by presenting clinical tumor stage, leading to satisfactory locoregional outcomes without affecting overall survival of patients, thus increasing considerably the rates of patients eligible for conservative treatment. 2. Keywords: Breast Cancer; Conservative Treatment; Locoregional Recurrences; Neoadjuvant Chemotherapy
- 30 September 2014
- Published by American Association for Cancer Research (AACR)
- Vol. 74 (19 Supplem) , 5145
Abstract 5145: KDM2B expression regulates ribosome biogenesis and cancer cell growth in a p53-dependent manner
Ribosome biogenesis is a cellular process requiring a fine-tuned control, as its deregulation is linked to cancer progression. Indeed, tumors characterized by an intense ribosome biogenesis often display a more aggressive biological and clinical behavior. Ribosomal RNA (rRNA) synthesis is controlled at several levels, the higher one being the epigenetic regulation of chromatin portions containing rRNA genes. KDM2B (Lysine (K)-specific demethylase 2B) is a histone demethylase modulating the accessibility of rRNA genes, thereby repressing their transcription. In particular KDM2B is known to specifically act on trimethylated K4 of histone H3 (H3K4) associated with rDNA. In this study we aimed to define the contribution of KDM2B expression to the biological features of breast cancer, a tumor type whose clinical behavior is known to be related to the rate of ribosome biogenesis. We show that, in primary breast carcinomas, lower KDM2B expression correlates with an increased size of specifically stained nucleolar organizer regions, a morphological parameter directly related to the rate of ribosome biogenesis, and with a poorer prognosis. In vitro, in breast cancer-derived cell lines, siRNA mediated KDM2B knock-down (KD) induced an increase in H3K4 trimethylation and in rRNA transcription. However, this is mirrored by an augmented cell proliferation only in p53 compromised cells, while p53 competent cells undergo cellular senescence and death. The latter effect, appears to be mediated by a p38-mediated phosphorylation of p53, inducing the expression of p15Ink4b and p21Waf1, and is not linked to p53 stabilization. In the long term, stable KDM2B KD in p53-compromised breast cancer cells induced a series of additional biological features including their augmented cellular clonogenic potential and invasive capability. Altogether our data indicate that abnormal JHDM1B-mediated epigenetic activation of rDNA genes elicits a p53-mediated growth arrest, but may promote cancer cell growth when p53 is lacking. Citation Format: Marianna Penzo, Lucia Casoli, Laura Sicuro, Alice Galibiati, Daniela Pollutri, Marzia Govoni, Claudio Ceccarelli, Donatella Santini, Mario Taffurelli, Davide Treré, Lorenzo Montanaro. KDM2B expression regulates ribosome biogenesis and cancer cell growth in a p53-dependent manner. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5145. doi:10.1158/1538-7445.AM2014-5145
- 30 September 2014
- Published by American Association for Cancer Research (AACR)
- Vol. 74 (19 Supplem) , 5145
Abstract 5145: KDM2B expression regulates ribosome biogenesis and cancer cell growth in a p53-dependent manner
Ribosome biogenesis is a cellular process requiring a fine-tuned control, as its deregulation is linked to cancer progression. Indeed, tumors characterized by an intense ribosome biogenesis often display a more aggressive biological and clinical behavior. Ribosomal RNA (rRNA) synthesis is controlled at several levels, the higher one being the epigenetic regulation of chromatin portions containing rRNA genes. KDM2B (Lysine (K)-specific demethylase 2B) is a histone demethylase modulating the accessibility of rRNA genes, thereby repressing their transcription. In particular KDM2B is known to specifically act on trimethylated K4 of histone H3 (H3K4) associated with rDNA. In this study we aimed to define the contribution of KDM2B expression to the biological features of breast cancer, a tumor type whose clinical behavior is known to be related to the rate of ribosome biogenesis. We show that, in primary breast carcinomas, lower KDM2B expression correlates with an increased size of specifically stained nucleolar organizer regions, a morphological parameter directly related to the rate of ribosome biogenesis, and with a poorer prognosis. In vitro, in breast cancer-derived cell lines, siRNA mediated KDM2B knock-down (KD) induced an increase in H3K4 trimethylation and in rRNA transcription. However, this is mirrored by an augmented cell proliferation only in p53 compromised cells, while p53 competent cells undergo cellular senescence and death. The latter effect, appears to be mediated by a p38-mediated phosphorylation of p53, inducing the expression of p15Ink4b and p21Waf1, and is not linked to p53 stabilization. In the long term, stable KDM2B KD in p53-compromised breast cancer cells induced a series of additional biological features including their augmented cellular clonogenic potential and invasive capability. Altogether our data indicate that abnormal JHDM1B-mediated epigenetic activation of rDNA genes elicits a p53-mediated growth arrest, but may promote cancer cell growth when p53 is lacking. Citation Format: Marianna Penzo, Lucia Casoli, Laura Sicuro, Alice Galibiati, Daniela Pollutri, Marzia Govoni, Claudio Ceccarelli, Donatella Santini, Mario Taffurelli, Davide Treré, Lorenzo Montanaro. KDM2B expression regulates ribosome biogenesis and cancer cell growth in a p53-dependent manner. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5145. doi:10.1158/1538-7445.AM2014-5145
- 20 June 2006
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (18_suppl) , 10722
Evaluation of early response to primary systemic chemotherapy in breast cancer patients by 18FDG PET: Preliminary findings from the Arianna Project 01
10722 Background: Pathological complete remission after primary systemic chemotherapy (PSC) for early breast cancer (BC) correlates with a better prognosis in terms of survival. The Arianna Project 01 was designed to study the relationship between clinical, hystological, biological, gene-expression profile characteristics and response to PSC in BC pts. Methods: Pts treated with 6 cycles of adriamycin 60 mg/m2 and paclitaxel 200 mg/m2 were evaluated at baseline and before each cycle by physical exam, 18FDG-PET, circulating tumor cells and bio-markers (serum EGFR, VEGF, UPA, plasma PAI-I and the circulating portion of HER2/neu receptor). At baseline and every other cycle mammography, ultrasound and breast MRI were also done. This preliminary report is focused on the correlation between PET monitoring and pathological response. Changes in tumoral 18FDG uptake, expressed as Standardized Uptake Value (SUV), were compared with the hystopathological response assessed according to Miller-Payne scale, which estimates the Tumour Regression Grade (TRG). Results: Up to now 12 pts (T > 2 cm) have been enrolled in the study and 9 completed PSC and were submitted to surgery. Baseline PET was abnormal in all pts (SUVmax range: 3.9–17.1). No cases of complete pathological remission have been observed so far. In 2 pts the TRG was grade 4 ( > 90% reduction of tumor cells), TRG was grade 3 (30 to 90% reduction) in 3 cases, grade 2 (minor loss of tumor cells) in 4 cases. After the 1st, the 2nd and the 3rd cycle of PSC the SUV decrease (Δ SUV) in primary tumors was ≥ 50%, ≥ 75% and ≥ 85% only in the two pts that at the end of PSC obtained a TRG grade 4 (see table ). Conclusions: Our preliminary results suggest that an early prediction of pathological response by PET is possible and the optimal timing to perform PET during PSC could be after 2 or 3 cycles. The study is still ongoing and the relationship between evaluation performed by PET and by mammography, ultrasound and breast MRI will be presented at the ASCO meeting. [Table: see text] No significant financial relationships to disclose.
- 20 June 2006
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (18_suppl) , 10722
Evaluation of early response to primary systemic chemotherapy in breast cancer patients by 18FDG PET: Preliminary findings from the Arianna Project 01
10722 Background: Pathological complete remission after primary systemic chemotherapy (PSC) for early breast cancer (BC) correlates with a better prognosis in terms of survival. The Arianna Project 01 was designed to study the relationship between clinical, hystological, biological, gene-expression profile characteristics and response to PSC in BC pts. Methods: Pts treated with 6 cycles of adriamycin 60 mg/m2 and paclitaxel 200 mg/m2 were evaluated at baseline and before each cycle by physical exam, 18FDG-PET, circulating tumor cells and bio-markers (serum EGFR, VEGF, UPA, plasma PAI-I and the circulating portion of HER2/neu receptor). At baseline and every other cycle mammography, ultrasound and breast MRI were also done. This preliminary report is focused on the correlation between PET monitoring and pathological response. Changes in tumoral 18FDG uptake, expressed as Standardized Uptake Value (SUV), were compared with the hystopathological response assessed according to Miller-Payne scale, which estimates the Tumour Regression Grade (TRG). Results: Up to now 12 pts (T > 2 cm) have been enrolled in the study and 9 completed PSC and were submitted to surgery. Baseline PET was abnormal in all pts (SUVmax range: 3.9–17.1). No cases of complete pathological remission have been observed so far. In 2 pts the TRG was grade 4 ( > 90% reduction of tumor cells), TRG was grade 3 (30 to 90% reduction) in 3 cases, grade 2 (minor loss of tumor cells) in 4 cases. After the 1st, the 2nd and the 3rd cycle of PSC the SUV decrease (Δ SUV) in primary tumors was ≥ 50%, ≥ 75% and ≥ 85% only in the two pts that at the end of PSC obtained a TRG grade 4 (see table ). Conclusions: Our preliminary results suggest that an early prediction of pathological response by PET is possible and the optimal timing to perform PET during PSC could be after 2 or 3 cycles. The study is still ongoing and the relationship between evaluation performed by PET and by mammography, ultrasound and breast MRI will be presented at the ASCO meeting. [Table: see text] No significant financial relationships to disclose.
- 31 March 2006
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 32 (3) , 447-455
Skin Angiosarcoma Arising in an Irradiated Breast: Case-Report and Literature Review
BACKGROUND Angiosarcoma (AS) is a rare, invasive malignancy originating from endothelial cells caused by many different clinical situations. AS following radiotherapy for breast cancer after conservative surgery is a rare but well‐known association. OBJECTIVE The aim of this article is to describe a case of AS after breast conserving surgery and to review the literature to date. RESULTS We report the case of an 84‐year‐old woman who developed AS four years after she was subjected to quadrantectomy for invasive ductal cancer, followed by 30 tangent field radiotherapy sessions. She presented with a one‐month history or red papular skin eruptions on the operated breast. Skin lesions were submitted for biopsy, and they were positive for AS. The patients was subjected to surgical excision of the remaining breast including all AS lesions. She is alive with no evidence of disease after 10 months follow‐up. CONCLUSION Post‐radiotherapy AS is rare neoplasm, but it should be considered in the case of patients with red lesions after breast conserving surgery and adjuvant radiotherapy.
- 31 March 2006
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 32 (3) , 447-455
Skin Angiosarcoma Arising in an Irradiated Breast: Case-Report and Literature Review
BACKGROUND Angiosarcoma (AS) is a rare, invasive malignancy originating from endothelial cells caused by many different clinical situations. AS following radiotherapy for breast cancer after conservative surgery is a rare but well‐known association. OBJECTIVE The aim of this article is to describe a case of AS after breast conserving surgery and to review the literature to date. RESULTS We report the case of an 84‐year‐old woman who developed AS four years after she was subjected to quadrantectomy for invasive ductal cancer, followed by 30 tangent field radiotherapy sessions. She presented with a one‐month history or red papular skin eruptions on the operated breast. Skin lesions were submitted for biopsy, and they were positive for AS. The patients was subjected to surgical excision of the remaining breast including all AS lesions. She is alive with no evidence of disease after 10 months follow‐up. CONCLUSION Post‐radiotherapy AS is rare neoplasm, but it should be considered in the case of patients with red lesions after breast conserving surgery and adjuvant radiotherapy.